Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes

Clinical and Experimental Immunology

Volumn 116, Issue 3, 1999, Pages 388-394

  Hishii, M ^a   Kurnick, J T ^a   Ramirez Montagut, T ^a   Pandolfi, F ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c Viale Dell'Universita 37   (Italy)

Author keywords

Bcl 2 apoptosis; Cytotoxicity; Fas CD95; FasL; Perforin; Tumour infiltrating lymphocytes

Indexed keywords

FAS ANTIGEN; PERFORIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL CLONING; CELL LINE; CYTOLYSIS; CYTOTOXICITY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE CLONE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GLIOMA; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0033026548     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00879.x     Document Type: Article

References (61)

1. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile R. Tumor immunogenicity is determined by the mechanism of cell death via induction of heal shock protein expression. Nature Med 1998; 4:581-7.
2. Muller K, Mariani S, Matiba B, Kyewski B, Krammer P. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand. Eur J Immunol 1995; 25:2996-9.
3. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650-2.
4. Bachmann M, Ohteki T, Faienza K, Zakarian A, Kagi D, Speiser D, Ohashi P. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis. J Immunol 1997; 159:4165-70.
5. Fukuyama H, Adachi M, Suematsu S, Miwa K, Suda T, Yoshida N, Nagata S. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-1pr mice. J Immunol 1998; 160:3805-11.
6. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997; 90:1927-33.
7. Tsujimura K, Takahashi T, Iwase S, Matsudaira Y, Kaneko Y, Yagita H, Obata Y. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements. J Immunol 1998; 160:5253-61.
8. Jaattela Benedict M, Tewari M, Shayman J, Dixit V. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995; 10:2297-305.
9. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand A. Expression and function of the Fas antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995; 9:1227-32.
10. Lee R, Spielman J, Podack ER. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis. Int Immunol 1996; 8:991-1000.
11. Schroter M, Lowin B, Bomer C, Tschopp J. Regulation of Fas (Apo-1/ CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur J Immunol 1995; 25:3509-13.
12. Clark WH, Elder DE, Guerry D et al. Model predicting survival in stage 1 melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
13. Day C, Lew R, Mihm M et al. A multivariate analysis of prognostic factors for melanoma patients with lesions >3-65 mm in thickness. Ann Surg 1982; 195:44.
14. Mihm M, Clemente C, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-47.
15. Ridley A, Cavanagh JB. Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 1971; 94:117-24.
16. Mukherji B, Guha A, Chakraborty G, Sivanandham M, Nashed A, Sporn J, Ergin M. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989; 169:1961-76.
17. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168:1419-41.
18. Sensi M, Salvi S, Castelli C et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 1993; 178:1231-46.
19. Sensi M, Traversari C, Radrizzani M et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 1995; 92:5674-8.
20. Kumick J, Kradin R, Blumberg R, Schneeberger E, Boyle L. Functional characterisation of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38:367-80.
21. Platsoucas C. Human autologous tumor-specific T cells in malignant melanoma. Cancer Metastasis Rev 1991; 10:151-76.
22. Caignard A, Dietrich P, Morand V et al. Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. Cancer Res 1994; 54:1292-7.
23. Gervois N, Heuze F, Diez E, Jotereau F. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 1990; 20:825-31.
24. Ioannides C, Freedman R. Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumor-associated lymphocytes. Anticancer Res 1991; 11:1919-25.
25. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 1993; 53:3569-73.
26. Miescher S, Whiteside T, Moretta L, VonFliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 1987; 138:4004.
27. Pandolti F, Boyle L, Trentin L, Oliva A, Kurnick J. T cell receptor gene rearrangement and cytotoxic activities of clones isolated from tumor infiltrating lymphocytes from melanoma patients. Clin Exp Immunol 1994; 95:141-7.
28. Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ. T-cell recognition of ovarian cancer. Surg 1993; 114:227-34.
29. Rosenberg S, Packard B, Aebersold P. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. N Eng J Med 1988; 25:1676-80.
30. Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J Immunol 1989; 143:3404-11.
31. Kradin R, Kurnick J, Lazarus D et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; i: 577-80.
32. Hishii M, Andrews D, Boyle L, Wong J, Pandolfi F, van den Elsen P, Kurnick J. In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA 1997; 94:1378-83.
33. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes. Annu Rev Immunol 1994; 12:735-73.
34. Hehner S, Hofmann T, Ratter F, Dumont A, Droge W, Schmitz M, Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappaB are uncoupled in L929 cells. J Biol Chem 1998; 273:18117-21.
35. Kuwano K, Akashi A, Arai S. An anergic cytotoxic T lymphocyte clone exhibits granule exocytosis-mediated cytotoxicity. Cell Immunol 1998; 185:114-22.
36. Henkart P. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1994; 1:343-6.
37. Suda T, Magata S. Purification and characterisation of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179:873-9.
38. Owen JJ, Jenkinson EJ. Apoptosis and T-cell repertoire selection in the thymus. Ann NY Acad Sci 1992; 663:305-10.
39. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177:195-200.
40. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-43.
41. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152:1127-33.
42. Strack P, Martin C, Saito S, Dekruyff R, Ju S. Metabolic inhibitors distinguish cytolytic activity of CD4 and CD8 clones. Eur J Immunol 1990; 20:179-83.
43. Lancki D, Hsieh C, Fitch F, Mechanisms of lysis by cytologic T lymphocyte clones. J Immunol 1991; 146:3242-9.
44. Ozdemirli M, El-Khatib M, Bastiani L, Akdeniz H, Kuchroo V, Ju S. The cytotoxic process of CD4 Th1 clones. J Immunol 1992; 149:1889-95.
45. Ju ST, Cui H, Panka DJ, Ettinger R, Marshak RA. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91:4185-9.
46. Ramsdell F, Seaman MS, Miller RH, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express has ligand and to undergo activation-induced cell death. Intern Immunol 1994; 6:1545-53.
47. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181:781-6.
48. Anel A, Buferne M, Boyer C, Schmitt VA, Golstein P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol 1994; 24:2469-76.
49. Grogg D, Hahn S, Erb P. CD4+ T cell mediated killing of major histocompatibility complex class II-positive antigen-presenting cells. III. CD4+ cytotoxic T cells induce apoptosis of APC. J Immunol 1992; 22:267-79.
50. Miskovsky E, Liu A, Pavlat W et al. Studies of the mechanism of cytolysis by HIV-1 specific CD4+ human CTL clones induced by candidate AIDS vaccines. J Immunol 1994; 153:2787-99.
51. Susskind B, Shornick M, Iannotti M, Duffy B, nee Tanden P, Siegel J, Mohanakumar T. Cytolytic effector mechanisms of human CD4+cytotoxic T lymphocytes. Human Immunol 1996; 45:64-75.
52. Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51:3164-70.
53. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. Expression of cell adhesion molecules in human melanoma cell lines and their role in lymphocyte mediated cytotoxicity. Cancer 1992; 69:1165-73.
54. Kurnick J, Kradin R, Blumberg R, Schneeberger E, Boyle L. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38:367-80.
55. Kurnick J, Hayward A, Altevogt P. Helper and suppressor/inducer activity of human T cells and their cloned progeny maintained in long-term culture. J Immunol 1981; 126:1307.
56. Pandolfi F, Strong DM, Slease RB, Smith ML, Ortaldo JR, Herberman RB. Characterization of a suppressor T-cell chronic lymphocytic leukemia with ADCC but not NK activity. Blood 1980; 56:653-60.
57. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
58. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89:271-7.
59. Weller M, Frei K, Groscurth P, Krammer P, Yonekawa Y, Fontana A. Anti-Fas/Apo-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest 1994; 94:954-64.
60. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implication for tumor escape. Science 1996; 274:1363-6.
61. Yamauchi A, Taga K, Mostowski HS, Bloom ET. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. Blood 1996; 87:5127-35.